# Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT07284602** · PHASE3 · NOT_YET_RECRUITING · sponsor: **PureTech** · enrollment: 1100 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **DRUG:** Deupirfenidone
- **DRUG:** Pirfenidone (PFD)

## Key facts

- **NCT ID:** NCT07284602
- **Lead sponsor:** PureTech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2029-06
- **Final completion:** 2029-07
- **Target enrollment:** 1100 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07284602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07284602, "Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07284602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*